Fulcrum Therapeutics, Inc. (FULC) stock
Close on Nov 17, 2026Market cap $286.11MP/E –Yield –
Earnings
Fulcrum Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Fulcrum Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | Apr 27, 2026before the open | – | – | -$0.25 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026before the open | – | – | -$0.31 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025before the open | – | – | -$0.31 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 29, 2025before the open | – | – | -$0.28 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025before the open | – | – | -$0.31 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024before the open | $0 | -100.0% | -$0.35 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024before the open | $80.00M | +8788.9% | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024before the open | $0 | -100.0% | -$0.43 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024before the open | $900.00K | +28.6% | -$0.40 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $800.00K | -33.3% | -$0.39 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023before the open | $900.00K | -52.6% | -$0.38 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | $300.00K | -88.5% | -$0.41 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023before the open | $700.00K | -86.3% | -$0.50 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022before the open | $1.20M | -75.5% | -$0.51 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022before the open | $1.90M | – | -$0.83 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022before the open | $2.60M | – | -$0.64 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022before the open | $5.10M | – | -$0.58 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $4.90M | – | -$0.57 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 10, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 4, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 11, 2020before the open | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 13, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 5, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Fulcrum Therapeutics guided for has been reported
Guidance history
Every forecast Fulcrum Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 13, 2024 | cash burn | FY2025 | $55.00M – $65.00M | New |
| Nov 13, 2024 | cash, cash equivalents, and marketable securities | FY2024 | $240.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Fulcrum Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Results
- Results
- Results
- News
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Results
See a number that looks wrong?